Literature DB >> 25348148

Use of GLP-1 mimetic in type 2 diabetes mellitus: is it the end of fragility fractures?

Guillaume Mabilleau1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25348148     DOI： 10.1007/s12020-014-0461-1

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  10 in total

1.  Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy.

Authors:  Gherardo Mazziotti; Antonio Bianchi; Stefania Bonadonna; Monica Nuzzo; Vincenzo Cimino; Alessandra Fusco; Laura De Marinis; Andrea Giustina
Journal:  J Bone Miner Res       Date:  2006-04-05       Impact factor: 6.741

2.  Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture.

Authors:  Johanna H M Driessen; Hein A W van Onzenoort; Ronald M A Henry; Arief Lalmohamed; Joop P van den Bergh; Cees Neef; Hubert G M Leufkens; Frank de Vries
Journal:  Bone       Date:  2014-08-02       Impact factor: 4.398

3.  Prevalence of vertebral fractures in men with acromegaly.

Authors:  Gherardo Mazziotti; Antonio Bianchi; Stefania Bonadonna; Vincenzo Cimino; Ilaria Patelli; Alessandra Fusco; Alfredo Pontecorvi; Laura De Marinis; Andrea Giustina
Journal:  J Clin Endocrinol Metab       Date:  2008-09-30       Impact factor: 5.958

Review 4.  Biology of incretins: GLP-1 and GIP.

Authors:  Laurie L Baggio; Daniel J Drucker
Journal:  Gastroenterology       Date:  2007-05       Impact factor: 22.682

5.  Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor.

Authors:  Guillaume Mabilleau; Aleksandra Mieczkowska; Nigel Irwin; Peter R Flatt; Daniel Chappard
Journal:  J Endocrinol       Date:  2013-09-06       Impact factor: 4.286

6.  Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.

Authors:  Guillaume Mabilleau; Aleksandra Mieczkowska; Daniel Chappard
Journal:  J Diabetes       Date:  2013-11-22       Impact factor: 4.006

7.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Authors:  C F Deacon; A H Johnsen; J J Holst
Journal:  J Clin Endocrinol Metab       Date:  1995-03       Impact factor: 5.958

Review 8.  Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.

Authors:  Bin Su; Hui Sheng; Manna Zhang; Le Bu; Peng Yang; Liang Li; Fei Li; Chunjun Sheng; Yuqi Han; Shen Qu; Jiying Wang
Journal:  Endocrine       Date:  2014-07-30       Impact factor: 3.633

9.  Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.

Authors:  Tatiana Mancini; Gherardo Mazziotti; Mauro Doga; Rita Carpinteri; Niksa Simetovic; Pier Paolo Vescovi; Andrea Giustina
Journal:  Bone       Date:  2009-06-13       Impact factor: 4.398

10.  Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials.

Authors:  Matteo Monami; Ilaria Dicembrini; Alessandro Antenore; Edoardo Mannucci
Journal:  Diabetes Care       Date:  2011-11       Impact factor: 17.152
  10 in total
  1 in total

Review 1.  Diabetes in Cushing Disease.

Authors:  G Mazziotti; A M Formenti; S Frara; F Maffezzoni; M Doga; A Giustina
Journal:  Curr Diab Rep       Date:  2017-05       Impact factor: 4.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.